Sepracor Isomer of J&J Propulsid Could Expand Indications
Executive Summary
Janssen will fund investigation of Sepracor's norcisapride, a single-isomer version of the Johnson & Johnson subsidiary's Propulsid (cisapride), for bulimia, emesis and irritable bowel syndrome, as well as for Propulsid's current indication in gastroesophogeal reflux disease, Sepracor CEO Timothy Barberich reported in a July 21 conference call.
You may also be interested in...
Propulsid Physician Education On Cardiac Risk To Be Presented To Committee
Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011